Cargando…
BNT162b2 mRNA COVID-19 Vaccine Effectiveness in Patients with Coeliac Disease Autoimmunity: Real-World Data from Mass Vaccination Campaign
Background: Data on COVID-19 vaccine effectiveness among patients with coeliac disease are currently lacking because patients with immune conditions were excluded from clinical trials. We used our coeliac disease autoimmunity (CDA) cohort to explore the effectiveness of the BNT162b2 mRNA COVID-19 va...
Autores principales: | Ben-Tov, Amir, Lebwohl, Benjamin, Banon, Tamar, Chodick, Gabriel, Kariv, Revital, Assa, Amit, Gazit, Sivan, Patalon, Tal |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10534420/ https://www.ncbi.nlm.nih.gov/pubmed/37766374 http://dx.doi.org/10.3390/v15091968 |
Ejemplares similares
-
BNT162b2 Messenger RNA COVID-19 Vaccine Effectiveness in Patients With Inflammatory Bowel Disease: Preliminary Real-World Data During Mass Vaccination Campaign
por: Ben-Tov, Amir, et al.
Publicado: (2021) -
Assessment of Effectiveness of 1 Dose of BNT162b2 Vaccine for SARS-CoV-2 Infection 13 to 24 Days After Immunization
por: Chodick, Gabriel, et al.
Publicado: (2021) -
Kinetics of SARS-CoV-2 anti-S IgG after BNT162b2 vaccination
por: Grupel, Daniel, et al.
Publicado: (2021) -
Waning Effectiveness of the BNT162b2 Vaccine Against Infection in Adolescents
por: Prunas, Ottavia, et al.
Publicado: (2022) -
Waning effectiveness of the third dose of the BNT162b2 mRNA COVID-19 vaccine
por: Patalon, Tal, et al.
Publicado: (2022)